FRONT ENDOCRINOL 润色咨询

Frontiers in Endocrinology

出版年份:2010 年文章数:6588 投稿命中率: 开通期刊会员,数据随心看

出版周期:Irregular 自引率:4.3% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0<br>偏重的研究方向:糖尿病<br>经验分享:为什么我先被接受了,钱都交了,然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.<br>请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:生殖医学<br>经验分享:15 Apr 2024 Article accepted for publication.<br>10 Apr 2024 Review of Review Editor 3 finalized.<br>04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.<br>28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.<br>14 Mar 2024 Interactive review forum activated.<br>25 Jan 2024 Review of Reviewer 1 is finalized.<br>23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179419, encodeId=74f721e94197a, content=偏重的研究方向:甲状腺癌<br>经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Fri Jan 05 14:38:11 CST 2024, time=2024-01-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131250, encodeId=976c213125070, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:内分泌<br>经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:48:06 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2167281, encodeId=c94f216e28178, content=偏重的研究方向:癌症;Endocrinology<br>经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Nov 07 22:03:52 CST 2023, time=2023-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108928, encodeId=aef1210892807, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:糖尿病并发症<br>经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。<br>27 Dec 2022 Article rejected by Specialty Chief<br>22 Nov 2022 Review of Review Editor 1 finalized<br>21 Nov 2022 Review of Review Editor 3 finalized<br>14 Nov 2022 <br>Review of Review Editor 1 finalized<br>Corresponding Author re-submitted manuscript<br>You posted new comments<br>07 Nov 2022 <br>Interactive review forum activated<br>Review of Reviewer 3 is finalized<br>06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210722/ce07e4a5c3c140a6bb8f19209b4271a4/4355f14397864d6c8f0343fc06a29351.jpg, createdBy=614c5554341, createdName=ms1000000414896070, createdTime=Thu Jan 05 13:58:40 CST 2023, time=2023-01-05, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2176412, encodeId=95a621e641268, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:Received date: 17 Sep 2023<br>Editorial assignment start date: 26 Sep 2023<br>Independent review start date: 05 Oct 2023<br>Interactive review activated date: 12 Dec 2023<br>Review finalized date: 20 Dec 2023<br>目前是两个审稿专家都是:The Reviewer has finalized their report and endorsed the publication of this manuscript. <br>同时,The Associate Editor XXXX is evaluating any revisions made to the manuscript to take a final decision., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a73730185, createdName=yanglcau, createdTime=Thu Dec 21 22:33:43 CST 2023, time=2023-12-21, status=1, ipAttribution=河北省)]
    2022-12-15 大仑丁 来自湖北省

    审稿速度:1.0
    偏重的研究方向:糖尿病
    经验分享:为什么我先被接受了,钱都交了,然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final.

    14

    展开14条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0<br>偏重的研究方向:糖尿病<br>经验分享:为什么我先被接受了,钱都交了,然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.<br>请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:生殖医学<br>经验分享:15 Apr 2024 Article accepted for publication.<br>10 Apr 2024 Review of Review Editor 3 finalized.<br>04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.<br>28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.<br>14 Mar 2024 Interactive review forum activated.<br>25 Jan 2024 Review of Reviewer 1 is finalized.<br>23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179419, encodeId=74f721e94197a, content=偏重的研究方向:甲状腺癌<br>经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Fri Jan 05 14:38:11 CST 2024, time=2024-01-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131250, encodeId=976c213125070, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:内分泌<br>经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:48:06 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2167281, encodeId=c94f216e28178, content=偏重的研究方向:癌症;Endocrinology<br>经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Nov 07 22:03:52 CST 2023, time=2023-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108928, encodeId=aef1210892807, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:糖尿病并发症<br>经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。<br>27 Dec 2022 Article rejected by Specialty Chief<br>22 Nov 2022 Review of Review Editor 1 finalized<br>21 Nov 2022 Review of Review Editor 3 finalized<br>14 Nov 2022 <br>Review of Review Editor 1 finalized<br>Corresponding Author re-submitted manuscript<br>You posted new comments<br>07 Nov 2022 <br>Interactive review forum activated<br>Review of Reviewer 3 is finalized<br>06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210722/ce07e4a5c3c140a6bb8f19209b4271a4/4355f14397864d6c8f0343fc06a29351.jpg, createdBy=614c5554341, createdName=ms1000000414896070, createdTime=Thu Jan 05 13:58:40 CST 2023, time=2023-01-05, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2176412, encodeId=95a621e641268, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:Received date: 17 Sep 2023<br>Editorial assignment start date: 26 Sep 2023<br>Independent review start date: 05 Oct 2023<br>Interactive review activated date: 12 Dec 2023<br>Review finalized date: 20 Dec 2023<br>目前是两个审稿专家都是:The Reviewer has finalized their report and endorsed the publication of this manuscript. <br>同时,The Associate Editor XXXX is evaluating any revisions made to the manuscript to take a final decision., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a73730185, createdName=yanglcau, createdTime=Thu Dec 21 22:33:43 CST 2023, time=2023-12-21, status=1, ipAttribution=河北省)]
    2024-06-05 我要毕业2024 来自广东省

    请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0<br>偏重的研究方向:糖尿病<br>经验分享:为什么我先被接受了,钱都交了,然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.<br>请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:生殖医学<br>经验分享:15 Apr 2024 Article accepted for publication.<br>10 Apr 2024 Review of Review Editor 3 finalized.<br>04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.<br>28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.<br>14 Mar 2024 Interactive review forum activated.<br>25 Jan 2024 Review of Reviewer 1 is finalized.<br>23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179419, encodeId=74f721e94197a, content=偏重的研究方向:甲状腺癌<br>经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Fri Jan 05 14:38:11 CST 2024, time=2024-01-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131250, encodeId=976c213125070, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:内分泌<br>经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:48:06 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2167281, encodeId=c94f216e28178, content=偏重的研究方向:癌症;Endocrinology<br>经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Nov 07 22:03:52 CST 2023, time=2023-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108928, encodeId=aef1210892807, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:糖尿病并发症<br>经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。<br>27 Dec 2022 Article rejected by Specialty Chief<br>22 Nov 2022 Review of Review Editor 1 finalized<br>21 Nov 2022 Review of Review Editor 3 finalized<br>14 Nov 2022 <br>Review of Review Editor 1 finalized<br>Corresponding Author re-submitted manuscript<br>You posted new comments<br>07 Nov 2022 <br>Interactive review forum activated<br>Review of Reviewer 3 is finalized<br>06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210722/ce07e4a5c3c140a6bb8f19209b4271a4/4355f14397864d6c8f0343fc06a29351.jpg, createdBy=614c5554341, createdName=ms1000000414896070, createdTime=Thu Jan 05 13:58:40 CST 2023, time=2023-01-05, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2176412, encodeId=95a621e641268, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:Received date: 17 Sep 2023<br>Editorial assignment start date: 26 Sep 2023<br>Independent review start date: 05 Oct 2023<br>Interactive review activated date: 12 Dec 2023<br>Review finalized date: 20 Dec 2023<br>目前是两个审稿专家都是:The Reviewer has finalized their report and endorsed the publication of this manuscript. <br>同时,The Associate Editor XXXX is evaluating any revisions made to the manuscript to take a final decision., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a73730185, createdName=yanglcau, createdTime=Thu Dec 21 22:33:43 CST 2023, time=2023-12-21, status=1, ipAttribution=河北省)]
    2023-01-12 ms5000001329361729 来自河南省

    目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.
    请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们

    7

    展开7条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0<br>偏重的研究方向:糖尿病<br>经验分享:为什么我先被接受了,钱都交了,然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.<br>请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:生殖医学<br>经验分享:15 Apr 2024 Article accepted for publication.<br>10 Apr 2024 Review of Review Editor 3 finalized.<br>04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.<br>28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.<br>14 Mar 2024 Interactive review forum activated.<br>25 Jan 2024 Review of Reviewer 1 is finalized.<br>23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179419, encodeId=74f721e94197a, content=偏重的研究方向:甲状腺癌<br>经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Fri Jan 05 14:38:11 CST 2024, time=2024-01-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131250, encodeId=976c213125070, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:内分泌<br>经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:48:06 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2167281, encodeId=c94f216e28178, content=偏重的研究方向:癌症;Endocrinology<br>经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Nov 07 22:03:52 CST 2023, time=2023-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108928, encodeId=aef1210892807, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:糖尿病并发症<br>经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。<br>27 Dec 2022 Article rejected by Specialty Chief<br>22 Nov 2022 Review of Review Editor 1 finalized<br>21 Nov 2022 Review of Review Editor 3 finalized<br>14 Nov 2022 <br>Review of Review Editor 1 finalized<br>Corresponding Author re-submitted manuscript<br>You posted new comments<br>07 Nov 2022 <br>Interactive review forum activated<br>Review of Reviewer 3 is finalized<br>06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210722/ce07e4a5c3c140a6bb8f19209b4271a4/4355f14397864d6c8f0343fc06a29351.jpg, createdBy=614c5554341, createdName=ms1000000414896070, createdTime=Thu Jan 05 13:58:40 CST 2023, time=2023-01-05, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2176412, encodeId=95a621e641268, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:Received date: 17 Sep 2023<br>Editorial assignment start date: 26 Sep 2023<br>Independent review start date: 05 Oct 2023<br>Interactive review activated date: 12 Dec 2023<br>Review finalized date: 20 Dec 2023<br>目前是两个审稿专家都是:The Reviewer has finalized their report and endorsed the publication of this manuscript. <br>同时,The Associate Editor XXXX is evaluating any revisions made to the manuscript to take a final decision., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a73730185, createdName=yanglcau, createdTime=Thu Dec 21 22:33:43 CST 2023, time=2023-12-21, status=1, ipAttribution=河北省)]
    2024-04-15 125051b5m55(暂无昵称) 来自湖南省

    审稿速度:6.0 | 投稿命中率:75.0
    偏重的研究方向:生殖医学
    经验分享:15 Apr 2024 Article accepted for publication.
    10 Apr 2024 Review of Review Editor 3 finalized.
    04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.
    28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.
    14 Mar 2024 Interactive review forum activated.
    25 Jan 2024 Review of Reviewer 1 is finalized.
    23 Nov 2023 Corresponding Author Chen Wang submitted manuscript.

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0<br>偏重的研究方向:糖尿病<br>经验分享:为什么我先被接受了,钱都交了,然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.<br>请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:生殖医学<br>经验分享:15 Apr 2024 Article accepted for publication.<br>10 Apr 2024 Review of Review Editor 3 finalized.<br>04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.<br>28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.<br>14 Mar 2024 Interactive review forum activated.<br>25 Jan 2024 Review of Reviewer 1 is finalized.<br>23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179419, encodeId=74f721e94197a, content=偏重的研究方向:甲状腺癌<br>经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Fri Jan 05 14:38:11 CST 2024, time=2024-01-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131250, encodeId=976c213125070, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:内分泌<br>经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:48:06 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2167281, encodeId=c94f216e28178, content=偏重的研究方向:癌症;Endocrinology<br>经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Nov 07 22:03:52 CST 2023, time=2023-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108928, encodeId=aef1210892807, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:糖尿病并发症<br>经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。<br>27 Dec 2022 Article rejected by Specialty Chief<br>22 Nov 2022 Review of Review Editor 1 finalized<br>21 Nov 2022 Review of Review Editor 3 finalized<br>14 Nov 2022 <br>Review of Review Editor 1 finalized<br>Corresponding Author re-submitted manuscript<br>You posted new comments<br>07 Nov 2022 <br>Interactive review forum activated<br>Review of Reviewer 3 is finalized<br>06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210722/ce07e4a5c3c140a6bb8f19209b4271a4/4355f14397864d6c8f0343fc06a29351.jpg, createdBy=614c5554341, createdName=ms1000000414896070, createdTime=Thu Jan 05 13:58:40 CST 2023, time=2023-01-05, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2176412, encodeId=95a621e641268, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:Received date: 17 Sep 2023<br>Editorial assignment start date: 26 Sep 2023<br>Independent review start date: 05 Oct 2023<br>Interactive review activated date: 12 Dec 2023<br>Review finalized date: 20 Dec 2023<br>目前是两个审稿专家都是:The Reviewer has finalized their report and endorsed the publication of this manuscript. <br>同时,The Associate Editor XXXX is evaluating any revisions made to the manuscript to take a final decision., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a73730185, createdName=yanglcau, createdTime=Thu Dec 21 22:33:43 CST 2023, time=2023-12-21, status=1, ipAttribution=河北省)]
    2023-10-30 791313987 来自江苏省

    感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧...

    6

    展开6条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0<br>偏重的研究方向:糖尿病<br>经验分享:为什么我先被接受了,钱都交了,然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.<br>请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:生殖医学<br>经验分享:15 Apr 2024 Article accepted for publication.<br>10 Apr 2024 Review of Review Editor 3 finalized.<br>04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.<br>28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.<br>14 Mar 2024 Interactive review forum activated.<br>25 Jan 2024 Review of Reviewer 1 is finalized.<br>23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179419, encodeId=74f721e94197a, content=偏重的研究方向:甲状腺癌<br>经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Fri Jan 05 14:38:11 CST 2024, time=2024-01-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131250, encodeId=976c213125070, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:内分泌<br>经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:48:06 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2167281, encodeId=c94f216e28178, content=偏重的研究方向:癌症;Endocrinology<br>经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Nov 07 22:03:52 CST 2023, time=2023-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108928, encodeId=aef1210892807, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:糖尿病并发症<br>经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。<br>27 Dec 2022 Article rejected by Specialty Chief<br>22 Nov 2022 Review of Review Editor 1 finalized<br>21 Nov 2022 Review of Review Editor 3 finalized<br>14 Nov 2022 <br>Review of Review Editor 1 finalized<br>Corresponding Author re-submitted manuscript<br>You posted new comments<br>07 Nov 2022 <br>Interactive review forum activated<br>Review of Reviewer 3 is finalized<br>06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210722/ce07e4a5c3c140a6bb8f19209b4271a4/4355f14397864d6c8f0343fc06a29351.jpg, createdBy=614c5554341, createdName=ms1000000414896070, createdTime=Thu Jan 05 13:58:40 CST 2023, time=2023-01-05, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2176412, encodeId=95a621e641268, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:Received date: 17 Sep 2023<br>Editorial assignment start date: 26 Sep 2023<br>Independent review start date: 05 Oct 2023<br>Interactive review activated date: 12 Dec 2023<br>Review finalized date: 20 Dec 2023<br>目前是两个审稿专家都是:The Reviewer has finalized their report and endorsed the publication of this manuscript. <br>同时,The Associate Editor XXXX is evaluating any revisions made to the manuscript to take a final decision., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a73730185, createdName=yanglcau, createdTime=Thu Dec 21 22:33:43 CST 2023, time=2023-12-21, status=1, ipAttribution=河北省)]
    2024-01-05 发大文章带我一个二十作吧 来自上海

    偏重的研究方向:甲状腺癌
    经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接

    3

    展开3条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0<br>偏重的研究方向:糖尿病<br>经验分享:为什么我先被接受了,钱都交了,然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.<br>请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:生殖医学<br>经验分享:15 Apr 2024 Article accepted for publication.<br>10 Apr 2024 Review of Review Editor 3 finalized.<br>04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.<br>28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.<br>14 Mar 2024 Interactive review forum activated.<br>25 Jan 2024 Review of Reviewer 1 is finalized.<br>23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179419, encodeId=74f721e94197a, content=偏重的研究方向:甲状腺癌<br>经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Fri Jan 05 14:38:11 CST 2024, time=2024-01-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131250, encodeId=976c213125070, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:内分泌<br>经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:48:06 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2167281, encodeId=c94f216e28178, content=偏重的研究方向:癌症;Endocrinology<br>经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Nov 07 22:03:52 CST 2023, time=2023-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108928, encodeId=aef1210892807, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:糖尿病并发症<br>经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。<br>27 Dec 2022 Article rejected by Specialty Chief<br>22 Nov 2022 Review of Review Editor 1 finalized<br>21 Nov 2022 Review of Review Editor 3 finalized<br>14 Nov 2022 <br>Review of Review Editor 1 finalized<br>Corresponding Author re-submitted manuscript<br>You posted new comments<br>07 Nov 2022 <br>Interactive review forum activated<br>Review of Reviewer 3 is finalized<br>06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210722/ce07e4a5c3c140a6bb8f19209b4271a4/4355f14397864d6c8f0343fc06a29351.jpg, createdBy=614c5554341, createdName=ms1000000414896070, createdTime=Thu Jan 05 13:58:40 CST 2023, time=2023-01-05, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2176412, encodeId=95a621e641268, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:Received date: 17 Sep 2023<br>Editorial assignment start date: 26 Sep 2023<br>Independent review start date: 05 Oct 2023<br>Interactive review activated date: 12 Dec 2023<br>Review finalized date: 20 Dec 2023<br>目前是两个审稿专家都是:The Reviewer has finalized their report and endorsed the publication of this manuscript. <br>同时,The Associate Editor XXXX is evaluating any revisions made to the manuscript to take a final decision., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a73730185, createdName=yanglcau, createdTime=Thu Dec 21 22:33:43 CST 2023, time=2023-12-21, status=1, ipAttribution=河北省)]
    2023-05-09 ms7000000507856696 来自江苏省

    审稿速度:2.0 | 投稿命中率:95.0
    偏重的研究方向:内分泌
    经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。

    5

    展开5条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0<br>偏重的研究方向:糖尿病<br>经验分享:为什么我先被接受了,钱都交了,然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.<br>请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:生殖医学<br>经验分享:15 Apr 2024 Article accepted for publication.<br>10 Apr 2024 Review of Review Editor 3 finalized.<br>04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.<br>28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.<br>14 Mar 2024 Interactive review forum activated.<br>25 Jan 2024 Review of Reviewer 1 is finalized.<br>23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179419, encodeId=74f721e94197a, content=偏重的研究方向:甲状腺癌<br>经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Fri Jan 05 14:38:11 CST 2024, time=2024-01-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131250, encodeId=976c213125070, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:内分泌<br>经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:48:06 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2167281, encodeId=c94f216e28178, content=偏重的研究方向:癌症;Endocrinology<br>经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Nov 07 22:03:52 CST 2023, time=2023-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108928, encodeId=aef1210892807, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:糖尿病并发症<br>经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。<br>27 Dec 2022 Article rejected by Specialty Chief<br>22 Nov 2022 Review of Review Editor 1 finalized<br>21 Nov 2022 Review of Review Editor 3 finalized<br>14 Nov 2022 <br>Review of Review Editor 1 finalized<br>Corresponding Author re-submitted manuscript<br>You posted new comments<br>07 Nov 2022 <br>Interactive review forum activated<br>Review of Reviewer 3 is finalized<br>06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210722/ce07e4a5c3c140a6bb8f19209b4271a4/4355f14397864d6c8f0343fc06a29351.jpg, createdBy=614c5554341, createdName=ms1000000414896070, createdTime=Thu Jan 05 13:58:40 CST 2023, time=2023-01-05, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2176412, encodeId=95a621e641268, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:Received date: 17 Sep 2023<br>Editorial assignment start date: 26 Sep 2023<br>Independent review start date: 05 Oct 2023<br>Interactive review activated date: 12 Dec 2023<br>Review finalized date: 20 Dec 2023<br>目前是两个审稿专家都是:The Reviewer has finalized their report and endorsed the publication of this manuscript. <br>同时,The Associate Editor XXXX is evaluating any revisions made to the manuscript to take a final decision., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a73730185, createdName=yanglcau, createdTime=Thu Dec 21 22:33:43 CST 2023, time=2023-12-21, status=1, ipAttribution=河北省)]
    2023-11-07 Doctorfan 来自上海

    偏重的研究方向:癌症;Endocrinology
    经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0<br>偏重的研究方向:糖尿病<br>经验分享:为什么我先被接受了,钱都交了,然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.<br>请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:生殖医学<br>经验分享:15 Apr 2024 Article accepted for publication.<br>10 Apr 2024 Review of Review Editor 3 finalized.<br>04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.<br>28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.<br>14 Mar 2024 Interactive review forum activated.<br>25 Jan 2024 Review of Reviewer 1 is finalized.<br>23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179419, encodeId=74f721e94197a, content=偏重的研究方向:甲状腺癌<br>经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Fri Jan 05 14:38:11 CST 2024, time=2024-01-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131250, encodeId=976c213125070, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:内分泌<br>经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:48:06 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2167281, encodeId=c94f216e28178, content=偏重的研究方向:癌症;Endocrinology<br>经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Nov 07 22:03:52 CST 2023, time=2023-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108928, encodeId=aef1210892807, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:糖尿病并发症<br>经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。<br>27 Dec 2022 Article rejected by Specialty Chief<br>22 Nov 2022 Review of Review Editor 1 finalized<br>21 Nov 2022 Review of Review Editor 3 finalized<br>14 Nov 2022 <br>Review of Review Editor 1 finalized<br>Corresponding Author re-submitted manuscript<br>You posted new comments<br>07 Nov 2022 <br>Interactive review forum activated<br>Review of Reviewer 3 is finalized<br>06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210722/ce07e4a5c3c140a6bb8f19209b4271a4/4355f14397864d6c8f0343fc06a29351.jpg, createdBy=614c5554341, createdName=ms1000000414896070, createdTime=Thu Jan 05 13:58:40 CST 2023, time=2023-01-05, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2176412, encodeId=95a621e641268, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:Received date: 17 Sep 2023<br>Editorial assignment start date: 26 Sep 2023<br>Independent review start date: 05 Oct 2023<br>Interactive review activated date: 12 Dec 2023<br>Review finalized date: 20 Dec 2023<br>目前是两个审稿专家都是:The Reviewer has finalized their report and endorsed the publication of this manuscript. <br>同时,The Associate Editor XXXX is evaluating any revisions made to the manuscript to take a final decision., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a73730185, createdName=yanglcau, createdTime=Thu Dec 21 22:33:43 CST 2023, time=2023-12-21, status=1, ipAttribution=河北省)]
    2023-01-05 ms1000000414896070 来自吉林省

    审稿速度:6.0 | 投稿命中率:25.0
    偏重的研究方向:糖尿病并发症
    经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。
    27 Dec 2022 Article rejected by Specialty Chief
    22 Nov 2022 Review of Review Editor 1 finalized
    21 Nov 2022 Review of Review Editor 3 finalized
    14 Nov 2022
    Review of Review Editor 1 finalized
    Corresponding Author re-submitted manuscript
    You posted new comments
    07 Nov 2022
    Interactive review forum activated
    Review of Reviewer 3 is finalized
    06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None

    3

    展开3条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0<br>偏重的研究方向:糖尿病<br>经验分享:为什么我先被接受了,钱都交了,然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.<br>请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:生殖医学<br>经验分享:15 Apr 2024 Article accepted for publication.<br>10 Apr 2024 Review of Review Editor 3 finalized.<br>04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.<br>28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.<br>14 Mar 2024 Interactive review forum activated.<br>25 Jan 2024 Review of Reviewer 1 is finalized.<br>23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179419, encodeId=74f721e94197a, content=偏重的研究方向:甲状腺癌<br>经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Fri Jan 05 14:38:11 CST 2024, time=2024-01-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131250, encodeId=976c213125070, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:内分泌<br>经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:48:06 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2167281, encodeId=c94f216e28178, content=偏重的研究方向:癌症;Endocrinology<br>经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Nov 07 22:03:52 CST 2023, time=2023-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108928, encodeId=aef1210892807, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:糖尿病并发症<br>经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。<br>27 Dec 2022 Article rejected by Specialty Chief<br>22 Nov 2022 Review of Review Editor 1 finalized<br>21 Nov 2022 Review of Review Editor 3 finalized<br>14 Nov 2022 <br>Review of Review Editor 1 finalized<br>Corresponding Author re-submitted manuscript<br>You posted new comments<br>07 Nov 2022 <br>Interactive review forum activated<br>Review of Reviewer 3 is finalized<br>06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210722/ce07e4a5c3c140a6bb8f19209b4271a4/4355f14397864d6c8f0343fc06a29351.jpg, createdBy=614c5554341, createdName=ms1000000414896070, createdTime=Thu Jan 05 13:58:40 CST 2023, time=2023-01-05, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2176412, encodeId=95a621e641268, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:Received date: 17 Sep 2023<br>Editorial assignment start date: 26 Sep 2023<br>Independent review start date: 05 Oct 2023<br>Interactive review activated date: 12 Dec 2023<br>Review finalized date: 20 Dec 2023<br>目前是两个审稿专家都是:The Reviewer has finalized their report and endorsed the publication of this manuscript. <br>同时,The Associate Editor XXXX is evaluating any revisions made to the manuscript to take a final decision., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a73730185, createdName=yanglcau, createdTime=Thu Dec 21 22:33:43 CST 2023, time=2023-12-21, status=1, ipAttribution=河北省)]
    2023-12-21 yanglcau 来自河北省

    审稿速度:3.0 | 投稿命中率:50.0
    经验分享:Received date: 17 Sep 2023
    Editorial assignment start date: 26 Sep 2023
    Independent review start date: 05 Oct 2023
    Interactive review activated date: 12 Dec 2023
    Review finalized date: 20 Dec 2023
    目前是两个审稿专家都是:The Reviewer has finalized their report and endorsed the publication of this manuscript.
    同时,The Associate Editor XXXX is evaluating any revisions made to the manuscript to take a final decision.

    6

    展开6条回复
共500条页码: 1/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分